They reported a balanced accuracy of 85.6% for 2-class glioma IDH1 mutation prediction, 56.2% at 5-class glioma subtyping, 88.3% at 12-class brain tumor cancer classification, and 67.5% at a 30-class brain tumor subtyping task. The gene discussed is IDH1; the disease is central nervous system cancer.